Press Releases

For press releases issued prior to June 2, 2014, the date of the spin-off of Theravance Biopharma, Inc. from Theravance, Inc., please visit Innoviva, Inc.

Date Title  
02/21/19
DUBLIN , Feb. 21, 2019 /PRNewswire/ --   Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that management will participate in a fireside chat at the 8 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 , at 9:00 a.m. ET .
02/19/19
In the news release, Theravance Biopharma to Report Fourth Quarter and Full Year 2018 Financial Results on February 26 , issued 19-Feb-2019 by Theravance Biopharma, Inc. over PR Newswire, we are advised by the company that date in the second paragraph, first sentence, should read " February 26,
01/28/19
Study to evaluate novel, once-daily ampreloxetine in symptomatic nOH patients with primary autonomic failure, including multiple system atrophy, Parkinson's disease, and pure autonomic failure DUBLIN , Jan. 28, 2019 /PRNewswire/ --  Theravance Biopharma, Inc.
01/07/19
DUBLIN , Jan. 7, 2019 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today announced a reduction in workforce to align with its focus on continued execution of key strategic programs, and advancement of selected late-stage research programs
12/04/18
DUBLIN , Dec. 4, 2018 /PRNewswire/ --  Theravance Biopharma, Inc.  (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") will host an R&D Day from 12:00 p.m. ET to 3:00 p.m. ET on Wednesday, December 12, 2018 , in New York City . Theravance Biopharma management and R&D teams will provide an
12/03/18
DUBLIN , Dec. 3, 2018 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " and together with its subsidiaries, the "Company") today announced the closing of a private placement of $250 million of non-recourse PhaRMA SM   9% fixed rate term notes.
11/27/18
First-in-Human Study for Novel, Inhaled, Lung-Selective pan-Janus Kinase (JAK) Inhibitor with Potentially Broad Activity Across Range of Serious Respiratory Diseases DUBLIN , Nov. 27, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today
11/20/18
Study to Evaluate Novel, Potent, Orally Administered and Gut-Selective pan-Janus Kinase (JAK) Inhibitor in Patients with Moderately to Severely Active Crohn's Disease DUBLIN , Nov. 20, 2018 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma " or the "Company") today
11/19/18
DUBLIN , Nov. 19, 2018 /PRNewswire/ --  Theravance Biopharma, Inc. (NASDAQ: TBPH) announced today that members of management will participate in fireside chats at two upcoming investor conferences: 2018 Evercore ISI HealthCONx Conference on Tuesday, November 27, 2018 at 3:50 p.m. ET .
11/12/18
DUBLIN , Nov. 12, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") today highlighted that the European Commission authorized an expanded label for once-daily Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI'), recognizing the